Recurrent Vulvovaginal Candidiasis

Drug	Drug Name	Drug Description
DB12471	Ibrexafungerp	A triterpene antifungal indicated in the treatment of vulvovaginal candidiasis and prevention of recurrent vulvovaginal candidiasis in post-menarchal patients.
DB13055	Oteseconazole	An azole antifungal used to prevent recurrent vulvovaginal candidiasis in females who are not of reproductive potential.

Drug	Drug Name	Target	Type
DB12471	Ibrexafungerp	Cytochrome P450 3A4	enzyme
DB12471	Ibrexafungerp	UDP-glucuronosyltransferases (UGTs)	enzyme
DB12471	Ibrexafungerp	Sulfotransferase	enzyme
DB12471	Ibrexafungerp	Cytochrome P450 2C8	enzyme
DB12471	Ibrexafungerp	P-glycoprotein 1	transporter
DB12471	Ibrexafungerp	Solute carrier organic anion transporter family member 1B3	transporter
DB12471	Ibrexafungerp	Serum albumin	carrier
DB12471	Ibrexafungerp	1,3-beta-glucan synthase component GSC2	target
DB12471	Ibrexafungerp	GTP-binding protein RHO1	target
DB13055	Oteseconazole	Cytochrome P450 51	target
DB13055	Oteseconazole	ATP-binding cassette sub-family G member 2	transporter

Drug	Drug Name	Phase	Status	Count
DB13055	Oteseconazole	2	Completed	1
DB00196	Fluconazole	2 / 3	Active Not Recruiting	1
DB14123	Menthol	2 / 3	Active Not Recruiting	1
DB00196	Fluconazole	3	Completed	2
DB00196	Fluconazole	3	Recruiting	1
DB12471	Ibrexafungerp	3	Completed	2
DB13055	Oteseconazole	3	Completed	3
DB00945	Acetylsalicylic acid	4	Recruiting	1
DB00257	Clotrimazole	4	Recruiting	1
DB15823	Lactobacillus acidophilus	4	Recruiting	1
DB16540	Lactobacillus delbrueckii bulgaricus	4	Recruiting	1
DB00196	Fluconazole	Not Available	Enrolling by Invitation	1